Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics and Malpractice Statement

AI policies

Indexing and Abstracting

Peer Review Process

Journal Metrics

Expanding the phenotypic spectrum of RNASEH2B mutations: A new case of pure hereditary spastic paraplegia and a systematic review

Articles in Press

Document Type : Original Article

Authors

1 1 Genetics research center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 2 CHU Sainte Justine Research Center, University of Montreal, Montréal, Canada

2 Genetics research center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

3 Department of Neurology, The Five Senses Health Institute, Iran University of Medical Sciences, Tehran, Iran

4 1 Genetics research center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 2 Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Pathogenic variants in the RNASEH2B gene have been linked to Aicardi-Goutières syndrome type II (AGS-II), an early-onset encephalopathy that exhibits phenotypic overlaps with other neurodegenerative diseases, such as hereditary spastic paraplegia (HSP). A poor genotype-phenotype correlation, inconsistent findings in biomarker results of patients, and the challenge of distinguishing AGS-II from HSP underscore the necessity of performing comprehensive studies to address current difficulties in RNASEH2B-related cases. Here, through a detailed case report and comprehensive systematic review, we highlight clinical heterogeneity of RNASEH2B-related neurodegenerative cases and support the current view of considering RNASEH2B as an HSP-causing gene.
Methods: Using whole exome sequencing (WES), we identified an RNASEH2B variant, c.529G>A (p.Ala177Thr), in an Iranian patient suspected of having HSP, a mutation commonly reported in AGS-II. In contrast to AGS-II, clinical studies of the Iranian case were dominated by non-progressive HSP. A subsequent Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided review of RNASEH2B-related neurodegenerative disorders identified 49 relevant cases from 349 studies, revealing a variable spectrum of phenotypes. 
Results: These phenotypes were classified into three overlapping categories: “RNASEH2B-related AGS”, “atypical AGS-II”, and “RNASEH2B-related HSP”. 95 cases were diagnosed as RNASEH2B-related AGS or atypical AGS-II; six were classified as RNASEH2B-related HSP. One case was asymptomatic, and another involved intrauterine fetal death.
Conclusion: The current study highlights the expanding phenotypic spectrum of RNASEH2B mutations, emphasizing their potential to manifest as isolated pure HSP (pHSP) rather than classical AGS. This study underscores the importance of raising clinical awareness and incorporating genetic testing, particularly for atypical RNASEH2B cases.

Keywords

Main Subjects

References
  1. Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. Febs j 2009; 276(6): 1494-505.
  2. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988; 85(14): 5011-5.
  3. Videira G, Malaquias MJ, Laranjinha I, Martins R, Taipa R, Magalhães M. Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series. Mov Disord Clin Pract 2020; 7(3): 303-7.
  4. Elsayed LEO, Eltazi IZ, Ahmed AE, Stevanin G. Insights into Clinical, Genetic, and Pathological Aspects of Hereditary Spastic Paraplegias: A Comprehensive Overview. Front Mol Biosci 2021; 8: 690899.
  5. de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB. Hereditary Spastic Paraplegia: Clinical and Genetic Hallmarks. Cerebellum 2017; 16(2): 525-51.
  6. Kara E, Tucci A, Manzoni C, Lynch DS, Elpidorou M, Bettencourt C, et al. Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain 2016; 139(Pt 7): 1904-18.
  7. Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. Rev Neurol (Paris) 2015; 171(6-7): 505-30.
  8. Finsterer J, Löscher W, Quasthoff S, Wanschitz J, Auer-Grumbach M, Stevanin G. Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci 2012; 318(1-2): 1-18.
  9. Agarwal A, Garg D, Garg A, Srivastava AK. RNASEH2B Pathogenic Mutation Presenting with Pure, Apparently Non-Progressive Hereditary Spastic Paraparesis. Ann Indian Acad Neurol 2023; 26(6): 1013-4.
  10. Travaglini L, Aiello C, Stregapede F, D'Amico A, Alesi V, Ciolfi A, et al. The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes. Neurogenetics 2018; 19(2): 111-21.
  11. Spagnoli C, Frattini D, Salerno GG, Fusco C. RNASEH2B Pathogenic Gene Variant in Uncomplicated Hereditary Spastic Paraplegia: Report of a New Patient. Neuropediatrics 2018; 49(6): 419.
  12. Crow YJ, Zaki MS, Abdel-Hamid MS, Abdel-Salam G, Boespflug-Tanguy O, Cordeiro NJ, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics 2014; 45(6): 386-93.
  13. Noreau A, Dion PA, Rouleau GA. Molecular aspects of hereditary spastic paraplegia. Exp Cell Res 2014; 325(1): 18-26.
  14. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A 2015; 167a(2): 296-312.
  15. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 81(4): 713-25.
  16. Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol 2018; 14(2): 94-105.
  17. Grebenciucova E, Berger JR. Progressive Multifocal Leukoencephalopathy. Neurol Clin 2018; 36(4): 739-50.
  18. Hajati R, Emamikhah M, Danaee Fard F, Rohani M, Alavi A. Neurodegeneration with Brain Iron Accumulation and a Brief Report of the Disease in Iran. Can J Neurol Sci 2022; 49(3): 338-51.
  19. Khani M, Shamshiri H, Fatehi F, Rohani M, Haghi Ashtiani B, Akhoundi FH, et al. Description of combined ARHSP/JALS phenotype in some patients with SPG11 mutations. Mol Genet Genomic Med 2020; 8(7): e1240.
  20. Sadr Z, Zare-Abdollahi D, Rohani M, Alavi A. A founder mutation in COQ7, p.(Leu111Pro), causes pure hereditary spastic paraplegia (HSP) in the Iranian population. Neurol Sci 2023; 44(7): 2599-602.
  21. Hashemi SS, Zare-Abdollahi D, Bakhshandeh MK, Vafaee A, Abolhasani S, Inanloo Rahatloo K, et al. Clinical spectrum in multiple families with primary COQ(10) deficiency. Am J Med Genet A 2021; 185(2): 440-52.
  22. Erfanian Omidvar M, Torkamandi S, Rezaei S, Alipoor B, Omrani MD, Darvish H, et al. Genotype-phenotype associations in hereditary spastic paraplegia: a systematic review and meta-analysis on 13,570 patients. J Neurol 2021; 268(6): 2065-82.
  23. Schüle R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, et al. Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol 2016; 79(4): 646-58.
  24. Lynch DS, Koutsis G, Tucci A, Panas M, Baklou M, Breza M, et al. Hereditary spastic paraplegia in Greece: characterisation of a previously unexplored population using next-generation sequencing. Eur J Hum Genet 2016; 24(6): 857-63.
  25. Valencia CA, Husami A, Holle J, Johnson JA, Qian Y, Mathur A, et al. Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center's Experience. Front Pediatr 2015; 3: 67.
  26. Pashaei M, Davarzani A, Hajati R, Zamani B, Nafissi S, Larti F, et al. Description of clinical features and genetic analysis of one ultra-rare (SPG64) and two common forms (SPG5A and SPG15) of hereditary spastic paraplegia families. J Neurogenet 2021; 35(2): 84-94.
  27. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
  28. Beysen D, De Cordt C, Dielman C, Ogunjimi B, Dandelooy J, Reyniers E, et al. Genetic Testing Contributes to Diagnosis in Cerebral Palsy: Aicardi-Goutières Syndrome as an Example. Front Neurol 2021; 12: 617813.
  29. Alburaiky S, Dale RC, Crow YJ, Jones HF, Wassmer E, Melki I, et al. Opsoclonus-myoclonus in Aicardi-Goutières syndrome. Dev Med Child Neurol 2021; 63(12): 1483-6.
  30. Gippert S, Wagner M, Brunet T, Berruti R, Brugger M, Schwaibold EMC, et al. Exome sequencing (ES) of a pediatric cohort with chronic endocrine diseases: a single-center study (within the framework of the TRANSLATE-NAMSE project). Endocrine 2024; 85(1): 444-53.
  31. Pereira ER, Franklin GL, Raskin S, Teive HAG. Comment on: Diagnosis of Aicardi-Goutières Syndrome in Adults. Mov Disord Clin Pract 2020; 7(5): 583-4.
  32. Lambe J, Murphy OC, Mu W, Sondergaard Schatz K, Barañano KW, Venkatesan A. Relapsing-remitting clinical course expands the phenotype of Aicardi-Goutières syndrome. Ann Clin Transl Neurol 2020; 7(2): 254-8.
  33. Tonduti D, Izzo G, D'Arrigo S, Riva D, Moroni I, Zorzi G, et al. Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications. Mol Genet Metab 2019; 126(4): 489-94.
  34. Tonduti D, Panteghini C, Pichiecchio A, Decio A, Carecchio M, Reale C, et al. Encephalopathies with intracranial calcification in children: clinical and genetic characterization. Orphanet J Rare Dis 2018; 13(1): 135.
  35. Tüngler V, Schmidt F, Hieronimus S, Reyes-Velasco C, Lee-Kirsch MA. Phenotypic variability in a family with Aicardi-Goutières syndrome due to the common A177T RNASEH2B mutation. Case Rep Clin Med 2014; 3(3): 153-6.
  36. Kojima K, Baba M, Tsukiashi M, Nishimura T, Yasukawa K. RNA/DNA structures recognized by RNase H2. Brief Funct Genomics 2018; 18(3): 169-73.
  37. Chon H, Vassilev A, DePamphilis ML, Zhao Y, Zhang J, Burgers PM, et al. Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex. Nucleic Acids Res 2009; 37(1): 96-110.
  38. Bubeck D, Reijns MA, Graham SC, Astell KR, Jones EY, Jackson AP. PCNA directs type 2 RNase H activity on DNA replication and repair substrates. Nucleic Acids Res 2011; 39(9): 3652-66.
  39. Reijns MA, Bubeck D, Gibson LC, Graham SC, Baillie GS, Jones EY, et al. The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease. J Biol Chem 2011; 286(12): 10530-9.
  40. Figiel M, Chon H, Cerritelli SM, Cybulska M, Crouch RJ, Nowotny M. The structural and biochemical characterization of human RNase H2 complex reveals the molecular basis for substrate recognition and Aicardi-Goutières syndrome defects. J Biol Chem 2011; 286(12): 10540-50.
  41. Portale A, Mazzurco M, Portale L, Pavone P, Bertini E, Polizzi A, et al. Aicardi–Goutières Syndrome Type 2: A Report on Two Cases with Different Phenotypes Caused by RNASEH2B Gene Mutations. J Pediatr Neurol 2020; 18(04): 206-9.
  42. Landouré G, Zhu PP, Lourenço CM, Johnson JO, Toro C, Bricceno KV, et al. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. Hum Mutat 2013; 34(10): 1357-60.
  43. Orthmann-Murphy JL, Salsano E, Abrams CK, Bizzi A, Uziel G, Freidin MM, et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain 2009; 132(Pt 2): 426-38.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 08 October 2025
Files
Share
How to cite
Statistics